Risiko- und Schadensminimierung - wie wirksam sind sie?

Zusammenfassung

Der Forschungsstand zur Frage von Legitimation und Zukunft von schadensmindernden Strategien bei an sich unerwünschtem Verhalten wird diskutiert. Thematisch handelt es sich um Safer Use bei intravenösem Drogenkonsum, Strategien zur Prophylaxe bei Freizeitdrogenkonsum, Schadensminimierung durch Suchtmittelersatz, Safer Sex und weitere Maßnahmen zur Optimierung von Schadensminderung. Eine Integration wirksamer Maßnahmen in nationale Drogenpolitik ist möglich und wünschenswert, diese stehen nicht im Widerspruch zu Prävention und Behandlung. Für negative Auswirkungen von Schadensminimierung gibt es kaum Belege, Verbesserungen scheinen dennoch nötig.

Abstract

The research evidence for a legitimacy and for options of harm reduction strategies in the field of undesirable risk behavior is presented. This concerns safer use in injecting drug consumption, strategies to minimize harm in leisure time drug use, harm reduction through substitution treatments, safer sex and other measures for optimising harm reduction in a Public Health and and Public Order perspective. An intergration of such strategies into a comprehensive drug policy is feasible and recommendable, as they are not in contrast to prevention and treatment. Evidence for negative effects of harm reduction measures is scarce. Nevertheless, improvements are needed.

Schlüsselwörter

Schadensminderung - Risikominimierung - Drogenpolitik - Prophylaxe - Drogenkonsum - Safer Use

Key words

Harm reduction - risk minimizing - drug policy - drug use - safer use

Literatur

• 1 Miller M, Eskild A, Mella I. et al . Gender differences in stringe exchange programs use in Oslo, Norway.  Addiction. 2001;  96 1639-1651
• 2 Longshore D, Bluthenthal R N, Stein M D. Needle exchange programme: attendance and injection risk in Providence.  AIDS Education Prevention. 2001;  13 78-90
• 3 des J arlais DC, Friedman P, Grund J P. et al . HIV risk behaviour among participants of syringe exchange programmes in Central/Eastern Europe and Russia.  Internat J Drug Policy. 2002;  13 165-170
• 4 Rutter S, Dolan K, Wodak A. et al .Prison syringe exchange: a review of international research and program development. Sydney; National Drug and Alcohol Research Centre 2001
• 5 Stöver H, Nelles J. Ten years of experience with needle and syringe exchange programmes in European prisons.  International J Drug Policy. 2003;  14 437-444
• 6 Dolan K, Rutter S, Wodak A. Prison-based syringe exchange programmes: a review of international research and development.  Addiction. 2003;  98 153-158
• 7 Heinemann A, Gross U. Prevention of bloodborne virus infections among drug users in an open prison by syringe vending machines.  Sucht. 2001;  47 57-65
• 8 des J arlais DC, Friedman S R, Ward T P. Harm reduction: a public health response to the Aids epidemic among injecting drug users.  Annual Review Public Health. 1993;  14 413-450
• 9 Lurie P, Reingold A L. The public health impact of needle exchange programs in the United States and abroad. San Francisco; Institute for Health Policy Studies 1993
• 10 Gibson D R, Flynn N M, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users.  AIDS. 2001;  15 1329-1341
• 11 Doherty M C, Junge B, Rathouz B. et al . The effect of a needle exchange program on numbers of discarded needles: a 2-year follow-up.  Amer J Public Health. 2000;  90 936-939
• 12 Broadhead R S, Kerr T H, Grund J PC. et al . Safer injection facilities in North America: their place in public policy and health initiatives.  J Drug Issues. 2002;  32 329-356
• 13 MacDonald M, Law M, Kaldor J. et al . Effectiveness of needle and syringe programmes for preventing HIV transmission.  Internat J Drug Policy. 2003;  14 353-357
• 14 Kuo I, Brady J, Butler C. et al . Feasibility of referring drug users from a needle exchange program into an addiction treatment program: experience with a mobile treatment van and LAAM maintenance.  J Substance Abuse Treatment. 2003;  24 67-74
• 15 Bluthenthal R N, Gogineni A, Longshore D. et al . Factors associated with readiness to change drug use among needle-exchange users.  Drug Alcohol Dependence. 2001;  62 225-230
• 16 Riley E D, Safaeian M, Strathdee S A. et al . Drug user treatment referrals and entry among participants of a needle exchange programme.  Substance Use Misuse. 2002;  37 1869-1886
• 17 MacMaster S A, Vail K A. Demystifying the injection drug user: willingness to participate in traditional drug treatment services among participants in a needle exchange program.  J Psychoactive Drugs. 2002;  34 289-294
• 18 Hagan H, McGough J P, Thiede H. et al . Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors.  J Substance Abuse Treatment. 2000;  19 247-252
• 19 Stein M D, Charuvastra A, Maksad J. et al . A randomized trial of a brief alcohol intervention for needle exchangers.  Addiction. 2002;  97 691-700
• 20 Stein M D, Charuvastra A, Anderson B. et al . Alcohol and HIV risk taking among intravenous drug users.  Addictive Behaviors. 2002;  27 727-736
• 21 Baker A, Boggs T G, Lewin T J. Randomised controlled trial of brief cognitive-behavioural interventions among regular users of amphetamine.  Addiction. 2001;  96 1279-1287
• 22 Levounis P, Galanter M, Dermatis H. et al . Correlates of HIV transmission risk factors and considerations forinterventions in homeless, chemically addicted and mentally ill patients.  J Addictive Diseases. 2002;  21 61-72
• 23 Aitken C, Moore D, Higgs P. et al . The impact of a police crackdown on a street drug scene: evidence from the street.  Intern J Drug Policy. 2002;  13 189-198
• 24 Bluthenthal R N, Malik M R, Grau L E. et al . Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities.  Addiction. 2004;  99 1136-1146
• 25 McVeigh J, Beynon C, Bellis M A. New challenges for agency based syringe exchange schemes: analysis of 11 years of data (1991 - 2001) in Merseyside and Cheshire, United Kingdom.  Internat J Drug Policy. 2003;  14 399-405
• 26 Moatti J P, Vlahov D, Feroni I. et al . Multiple access to sterile syringes for injection drug users: vendine machines, needle exchange programs and legal pharmacy sales in Marseille, France.  Europ Addiction Research. 2001;  7 40-45
• 27 Wood E, Tyndall M W, Spittal P M. et al . Needle exchange and difficulty with needle access during an ongoing HIV epidemic.  Internat J Drug Policy. 2002;  13 95-102
• 28 Avants S K, Warburton L A, Hawkins K A. et al . Continuation of high-risk behavior by HIV-positive drug users’ treatment implications.  J Substance Abuse Treatment. 2002;  19 15-22
• 29 Caflisch C, Wang J, Zbinden R. The role of syringe filters in harm reduction among injecting drug users.  Amer J Public Health. 1999;  89 1252-1254
• 30 Grund J PC, Kaplan C D, Adriaans N FP. et al . Drug sharing and HIV transmission risks: the practice of „frontloading” in the Dutch injecting drug user population.  J Psychoactive Drugs. 1999;  23 1-10
• 31 WHO .Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva; World Health Organisation 2004
• 32 DHHS . U.S. Department of Health and Human Services.  Bulletin, April. 1993; 
• 33 Hughes R A. Drug injectors and the cleaning of needles and syringes.  Europ Addiction Research. 2000;  6 20-30
• 34 Hedrich D. European report on drug consumption rooms. Lisbon; European Monitoring Centre for Drugs and Drug Addiction EMCDDA 2004
• 35 Kerr T, Wood E, Palepu A. et al . Responding to an explosive HIV epidemic driven by frequent cocaine injection: is there a role for safe injecting facilities?.  J Drug Issues. 2003;  33 579-608
• 36 Ronco C, Spuhler G, Coda P. et al . Evaluation der Gassenzimmer I, II und III in Basel.  Sozial Präventivmedizin. 1996;  41 (Suppl 1) 58-68
• 37 Kemmesis U. The open drug scene and the safe injection room offers in Frankfurt am Main: final report. Münster; Indro 1999
• 38 Dolan K, Kimber J, Fry C. et al . Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia.  Drug Alcohol Review. 2000;  19 337-346
• 39 Happel V. Konsumräume. Eine effektive Maßnahme zur Schadensminderung bei DrogengebraucherInnen und BürgerInnen.  Akzeptanz. 2000;  8 30-36
• 40 Fischer B, Rehm J, Kim G. et al . Safer injecting facilities (SIFs) for injection drug users in Canada: a review and call for an evidence-focused pilot trial.  Canadian J Public Health. 2002;  93 336-338
• 41 Wright N MJ, Tompkins C NE. Supervised injecting centres.  Brit Med J. 2004;  328 100-102
• 42 EMCDDA. On-site pill-testing interventions in the European Union. Lisbon; European Monitoring Centre for Drugs and Drug Addiction 2001
• 43 Winstock A R, Wolff K, Ramsey J. Ecstasy pill testing: harm minimization gone too far?.  Addiction. 2001;  96 1139-1148
• 44 des J arlais DC, Friedman S R. HIV and intravenous drug use.  AIDS. 1988;  2 (Suppl 1) S65-S69
• 45 Hartgers C, van den Hoeck A, Krijnen P. et al . HIV prevalence and risk behavior among injecting drug users who participate in „low-threshold” methadone programs in Amsterdam.  Amer J Public Health. 1992;  82 547-551
• 46 Amadora-Nolasco F, Alburo R E, Aguilar E JT. et al . Knowledge and perception of risk for HIV and condor use among male injecting drug users in Cebu city, Phillipines.  Drug Alcohol Review. 1992;  21 137-143
• 47 Johnson R A, Gerstein G R, Pack A. et al . HIV risk behaviors in African-American drug injectors networks: implications of injection-partner mixing and partnership characteristics.  Addiction. 2002;  97 1011-1024
• 48 Broome K M, Joe G W, Simpson D D. HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences.  AIDS Education Prevention. 1999;  11 293-306
• 49 Jainchill N, Yagelka J, Hawke J. et al . Adolescent admissions to residential drug treatment: HIV risk behaviours pre- and posttreatment.  Psychology Addictive Behaviors. 1999;  13 163-173
• 50 Stall R D, Paul J P, Barrett D C. et al . An outcome evaluation to measures changes in sexual risk-taking among gay men undergoing substance use disorder treatment.  J Studies Alcohol. 1999;  60 837-845
• 51 Kral A H, Bluthenthal R N, Lorwick J. et al . Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis.  Lancet. 2001;  357 1397-1401
• 52 van Empelen P, Schaalma H P, Kok G. et al . Predicting condom use with casual and steady sex partners among drug users.  Health Education Research. 2001;  16 293-305
• 53 Compton W M, Cottler L B, Ben-Abdallah A. et al . The effects of psychiatric comorbidity on response to a HIV prevention intervention.  Drug Alcohol Dependence. 2000;  58 247-257
• 54 Ehrenstein V, Horton N J, Samet J H. Inconsistent condom use among HIV-infected patients with alcohol problems.  Drug Alcohol Dependence. 2004;  73 159-166
• 55 Caplehorn J RM, Dalton M SY, Cluff M C. et al . Retention in methadone maintenance and heroin addict’s risk of death.  Addiction. 1994;  89 203-207
• 56 Raschke P, Püschel K, Heinemann A. Rauschgiftmortalität und Substitutionstherapie in Hamburg.  Suchttherapie. 2000;  1 43-48
• 57 Mattick R, Degenhardt L. Methadone-related and heroin-related deaths among opiate users: methadone helps save lives.  Addiction. 2003;  98 (4) 419-425
• 58 Stenbacka M, Leifman A, Romelsjo A. The impact of methadone on consumption of inpatient care and mortality, with special reference to HIV status.  Subst Use Misuse. 1998;  33 (14) 2819-2834
• 59 Langendam M W, van Brussel G H, Coutinho R A. et al . The impact of harm-reduction-based methadone treatment on mortality among heroin users.  Am J Public Health. 2001;  91 (5) 774-780
• 60 Grönbladh L, Ohland L S, Gunne L M. Mortality in heroin addiction: impact of methadone treatment.  Acta Psychiat Scand. 1990;  82 223-227
• 61 Zador D A, Sunjic S D. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996.  Drug and Alcohol Review. 2002;  21 131-136
• 62 Wagner-Servais D, Erkens M. Methadone-related deaths associated with faulty induction procedures.  Journal of Maintenance in the Addictions. 2003;  2 57-67
• 63 Ward J, Mattick R P, Hall W. The effectiveness of methadone maintenance treatment: HIV and infectious hepatitis. Ward J, Mattick RP, Hall W Methadone maintenance: treatment and other opioid replacement therapies Amsterdam; Harwood 1995: 59-73
• 64 Marsch L A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis.  Addiction. 1998;  93 (4) 515-532
• 65 Caplehorn J RM, Ross M. Methadone maintenance and the likelihood of risky needle sharing.  Internat J Addictions. 1995;  30 685-698
• 66 Gowing L, Farrell M, Bornemann R. et al .Substitution treatment of injecting opioid users for prevention of HIV infection. Oxford; The Cochrane Library 2004
• 67 Metzger D S, Woody G E, McLellan A T. Human Immunodeficiency Virus (HIV) seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up.  Journal of Acquired Immune Deficiency Syndromes. 1993;  6 1049-1056
• 68 Moss A R, Vranizan K, Gorter R. et al . HIV seroconversion in intravenous drug users in San Francisco 1985 - 1990.  AIDS. 1994;  8 223-231
• 69 Gossop M, Marsden J, Steward D. et al . The National Treatment Outcome Research Study (NTORS): 4 - 5 year follow-up results. Addiction 2003; 98: 291 - 303. Gossop M, Marsden J, Stewart D et al. Reduction or cessation of injecting risk behaviours? Treatment outcomes at 1-year follow-up. Addictive Behaviors 2003; 28: 785 - 793. 
• 70 Ball J C, Ross A. The effectiveness of methadone maintenance treatment. New York; Springer 1991
• 71 Serpelloni G, Carrieri M P, Rezza G. et al . Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case control study.  AIDS Care. 1994;  16 215-220
• 72 Chaisson R E, Bacchetti P, Osmond D. et al . Cocaine use and HIV infection in intravenous drug users in San Francisco.  Journal of the American Medical Association. 1989;  261 561-565
• 73 Schoenbaum E E, Hartel D, Selwyn P A. et al . Risk factors for human immunodeficiency virus infection in intravenous drug users.  New England Journal of Medicine. 1989;  321 874-879
• 74 Avants S K, Margolin A, Warburton L A. et al . Predictors of nonadherence to HIV-related medication regimens during methadone stabilisation.  American Journal on Addictions. 2001;  10 69-78
• 75 Weber R, Ledergerber B, Opravil M. et al . Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with Methadone.  British Medical Journal. 1990;  301 1362-1365
• 76 Sorenson L, Copeland A M. Drug abuse treatment as an HIV prevention strategy: a review.  Drug Alcohol Dependence. 2000;  59 17-31
• 77 Zaric G S, Barnett P G, Brandeau M L. HIV transmission and the cost-effectiveness of methadone maintenance.  Amer J Public Health. 2000;  90 1100-1111
• 78 McLellan A T, Arndt I O, Woody G E. Psychosocial services in substance abuse treatment? A dose-ranging study of psychosocial services.  J Am Med Assn. 1993;  269 (15) 1953-1959
• 79 McLellan A T. The role of psychosocial services in drug abuse treatment. Waal H, Haga E Maintenance treatment in heroin addiction Oslo; Cappelen 2003: 267-295
• 80 van Ameijden E JC, van den Hoeck A AR, van Haastrecht H JA. et al . The harm reduction approach and risk factors for Human Immunodeficiency Virus (HIV) seroconversion among injecting drug users in Amsterdam.  Amer J Epidemiology. 1992;  136 236-243
• 81 Raschke P. Substitutionstherapie. Ergebnisse langfristiger Behandlung von Opiatabhängigen. Freiburg im Breisgau; Lambertus 1994
• 82 Fagerström K O, Hughes J R. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review.  Nicotine Tobacco Research. 2002;  4 (Suppl 2) 73-79
• 83 Shiffman S, Gorsline J, Gorodetzky C W. Efficacy of over the counter nicotine patch.  Nicotine Tobacco Research. 2002;  4 477-483
• 84 BAG ( Hrsg). Evaluationen des BAG im Suchtbereich 1990 - 2000. Bern; Bundesamt für Gesundheit 2002
• 85 Glover E D, Glover P N, Franzon M. et al . A comparison of a nicotine sublingual tablet and placebo for smoking cessation.  Nicotine Tobacco Research. 2002;  4 441-450
• 86 Hughes J R, Goldstein M G, Hurt R D. Recent advances on the pharmacotherapy of smoking.  JAMA. 1999;  281 72-81
• 87 Walsh R A, Penman A G. The effectiveness of nicotine replacement therapy over-the-counter.  Editorial Drug Alcohol Review. 2000;  19 243-248
• 88 Batra A, Buchkremer G. Die Dauer der Nikotinersatztherapie. Ein Prädiktor für die langfristige Abstinenz?.  Sucht. 2000;  46 414-423
• 89 Shiffman S, Hughes J R, Pillitteri J L. et al . Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample.  Tobacco Control. 2003;  12 310-316
• 90 International Narcotics Control Board (INCB).  Annual Report. 2004; 
• 91 Caulkins J P, Reuter P. Setting goals for drug policy: harm reduction or use reduction?.  Addiction. 1997;  92 1143-1150
• 92 MacCoun R J. The psychology of harm reduction: comparing alternative strategies for modifying high-risk behaviors.  Wellness Lectures. 1996;  6 5-27
• 93 Vogt R. Aktuelle Situation, Entwicklungen und Herausforderungen der Schadensverminderung.  Abhängigkeiten. 2002;  8 5-17
• 94 Killias M, Lamon P, Clerici C. et al .Tendances de la criminalité en Suisse de 1984 à 2000. Risques objectifs et perceptions subjectives. Lausanne; Institut de Police Scientifique et de Criminologie 2000
• 95 Killias M. Heroinverschreibung. Ein erfolgreiches Programm zur Kriminalitätsprävention.  Abhängigkeiten. 2004;  10 16-18